A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore: (ACROSS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01313494
First received: March 3, 2011
Last updated: July 31, 2013
Last verified: July 2013
  Purpose

The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.


Condition Intervention Phase
COPD
Drug: Roflumilast
Drug: Placebo
Drug: Salbutamol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.


Secondary Outcome Measures:
  • Change From Baseline in Post-bronchodilator FEV1 [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75% [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75% [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.

  • Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.

  • Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.

  • Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.

  • Change From Baseline in COPD Symptom Scores [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Symptoms of chronic bronchitis with respect to cough and sputum production were assessed daily by the patient and recorded in a diary. Symptoms were assessed on a 4-point scale as follows: Cough: 0: no cough; 1: mild cough (at some time during the day); 2: moderate cough (regularly during the day); 3: severe cough (never free of cough or feeling free of need to cough). Sputum production: 0: no sputum production (unnoticeable); 1: mild sputum production (noticeable as a problem); 2: moderate sputum production (frequent inconvenience); 3: severe sputum production (constant problem). Change from Baseline is reported for cough and sputum separately, and for the sum of the 2 scores (range 0 - 6). Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Change From Baseline in Use of Rescue Medication [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Salbutamol (given by metered dose inhaler and spacer) was used as rescue medication according to the individual needs of a patient. Each use was documented in the patient's paper diary. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Transition Dyspnoea Index (TDI) Total Score at Week 24 [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    The TDI is a recognized questionnaire to measure dyspnoea (shortness of breath) in patients with COPD. Questions from the TDI were used to assess the 3 components: "change in functional impairment", "change in magnitude of task" and "change in magnitude of effort". Transitions or changes from baseline are rated from -3 (major deterioration) to +3 (major improvement), and summed to give a total score ranging from -9 to +9. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

  • Percentage of Participants With Moderate or Severe COPD Exacerbations [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    A COPD exacerbation is an event characterised by a worsening in the patient's baseline dyspnoea, or cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management, and may be accompanied by increased wheeze, chest tightness, purulent sputum and symptoms of cold and/or fatigue. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

  • Mean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

    The mean rate of COPD exacerbations per patient per year rate = (number of exacerbations per treatment group/time to study withdrawal per treatment group) * 365. COPD exacerbations were categorized as follows:

    • Severe: Requiring hospitalization and/or leading to death;
    • Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

  • Time to Onset of First Moderate or Severe COPD Exacerbation [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

    Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. COPD exacerbations were categorized as follows:

    • Severe: Requiring hospitalization and/or leading to death;
    • Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

  • Time to Onset of Second Moderate or Severe COPD Exacerbation [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. At least 10 days between the stop date of an exacerbation and the start date of the following exacerbation was required for these to be be considered as two separate COPD exacerbations. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

  • Number of Participants With Adverse Events [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
    An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above. Each AE was assessed by the Investigator as either 'related' or 'not related' to study drug.


Enrollment: 626
Study Start Date: March 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Roflumilast
Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
Drug: Roflumilast
Roflumilast tablets
Drug: Salbutamol
Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
Placebo Comparator: Placebo
Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
Drug: Placebo
Placebo tablets
Drug: Salbutamol
Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Willingness to sign a written informed consent
  • Chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2009
  • Chinese or Malay or Indian ethnicity
  • History of chronic obstructive pulmonary disease symptoms for at least 12 months prior to baseline visit V0
  • Forced expiratory volume in the first second/ Forced vital capacity (FEV1/FVC) ratio (post-bronchodilator) < 70%
  • Forced expiratory volume in the first second (FEV1) (post-bronchodilator) < 50 % of predicted
  • Former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years

Main Exclusion Criteria:

  • Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics not stopped at V0
  • Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0
  • History of asthma diagnosis in patients < 40 years of age or relevant lung disease other than COPD
  • Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline visit V0
  • Known alpha-1-antitrypsin deficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01313494

Locations
China
Beijing, China
Changsha, China
Chengdu, China
Chongqing, China
Fuzhou, China
Guangzhou, China
Hangzhou, China
Nanjing, China
Nanning, China
Qingdao, China
Shanghai, China
Shenyang, China
Shijiazhuang, China
Hong Kong
Hong Kong, Hong Kong
Singapore
Singapore, Singapore
Sponsors and Collaborators
Takeda
  More Information

No publications provided by Takeda

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01313494     History of Changes
Other Study ID Numbers: RO-2455-301-RD, U1111-1133-6304
Study First Received: March 3, 2011
Results First Received: March 18, 2013
Last Updated: July 31, 2013
Health Authority: China: Food and Drug Administration
Hong Kong: Department of Health
Singapore: Health Sciences Authority

Keywords provided by Takeda:
COPD
Roflumilast
FEV1
China

Additional relevant MeSH terms:
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 22, 2014